Blue banner that says "Press Release"

Zero announces three top physicians to Medical Advisory Board

WASHINGTON, D.C., May 7, 2019 - Three prominent physicians have joined ZERO Prostate Cancer’s Medical Advisory Board. Elisabeth Heath, M.D., F.A.C.P., Rachel S. Rubin, M.D., and Charles J. Ryan, M.D. join ZERO’s esteemed group of leading medical professionals who are dedicated to helping men fight prostate cancer.

“All three of our new Medical Advisory Board members are nationally recognized for their work with prostate cancer patients and we were fortunate to feature them as speakers at the 2019 ZERO Prostate Cancer Summit in Washington, D.C. this past February,” said ZERO CEO and President Jamie Bearse. “Bringing these accomplished leaders onto our Medical Advisory Board allows us to tap their expertise year-round to help more patients and their families.”

Dr. Heath is the Patricia C. and E. Jan Hartmann endowed chair in Prostate Cancer Research at the Barbara Ann Karmanos Cancer Institute and professor of Oncology and Medicine at Wayne State University School of Medicine in Detroit, Michigan. Dr. Heath has more than 26 years of experience and is a leading patient advocate for the metro Detroit community. At the ZERO Prostate Cancer Summit, she spoke about funding clinical trials and how that translates into better care for prostate cancer patients.

Dr. Rubin is a urologic surgeon and fellowship-trained sexual medicine specialist. She believes in comprehensive, multidisciplinary and customized care for patients and their partners suffering from sexual dysfunction. Her expertise includes erectile dysfunction, pelvic pain, penile curvature, low testosterone, low libido, urinary incontinence, and penile implants. Dr. Rubin is with IntimMedicine Specialists in Washington, D.C.

Dr. Ryan is Director of Hematology, Oncology and Transplantation at the University of Minnesota. His research is aimed at developing new therapies for patients with advanced and recurrent prostate cancer. Specifically, Dr. Ryan is focused on the development of new hormonal and targeted therapies for prostate cancer, biomarkers defining disease aggressiveness, and strategies to maximize survivorship for men on long-term treatment.

“These three doctors will help grow ZERO’s patient support programs and educational resources aimed at ensuring all prostate cancer patients get the support and information they need,” said ZERO CEO and President Jamie Bearse. “We’re honored to have them as part of the ZERO family.”

These new Medical Advisory Board members join current board members Alicia Morgans, M.D., M.P.H. (Chair), Tomasz Beer, M.D., Leo Giambarresi, Ph.D., Joanna Morales, Esq., Meredith Morgan, MSN, Kelvin Moses, M.D., Ph.D., Alison Sachs, MSW, CSW, OSW-C, Eric Shinohara, M.D., MSCI, Nilay M. Gandhi, M.D., Benjamin H. Lowentritt, M.D., F.A.C.S., and Gary M. Kirsh, M.D.

 


About ZERO Prostate Cancer

ZERO Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer and help all who are impacted. ZERO advances research, provides support, and creates solutions to achieve health equity to meet the most critical needs of our community. From early detection to survivorship, ZERO is the premier resource for prostate cancer patients and their families to access comprehensive support, make meaningful connections, and take action to save lives. Our dedicated national and chapter staff is joined with a growing team of passionate volunteer champions to increase advocacy, awareness, and community engagement to ZERO out prostate cancer. ZERO is recognized with four out of four stars by Charity Navigator and accredited by the Better Business Bureau. ZERO spends more on programs than any other prostate cancer charity, dedicating 85 cents of every dollar to support, education, and research.

Share